HIV Protease Cleavage of Procaspase 8 is Necessary for Death of HIV-Infected Cells
Zilin Nie1, §, Gary D Bren1, §, Stacey A Rizza1, 2, Andrew D Badley*, 1, 2
1 Division of Infectious Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
2 Program in Translational Immunovirology and Biodefense, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Numerous host and viral factors are capable of causing death of HIV infected cells, uninfected bystander cells, or both. We assessed the relevance of HIV protease in infected cell killing by mutating its obligate substrate for death, procaspase 8. VSV pseudotyped HIV infection of cells expressing WT caspase 8 resulted in apoptotic cell death and generation of the HIV protease specific cleavage product of procaspase 8, casp8p41. Conversely, both cell death and casp8p41 production were inhibited in cells expressing procaspase 8 engineered to be resistant to HIV protease cleavage. Lymph nodes from HIV-infected patients with ongoing viral replication also selectively expressed casp8p41, which colocalized with both infected and apoptotic cells. HIV protease cleavage of procaspase 8 appears to be a necessary event for infected cell killing, which is responsible for infected cell death within lymphoid tissues from HIV-infected patients.
Received Date: 27/12/2007 Revision Received Date: 8/1/2008 Acceptance Date: 11/1/2008 Electronic publication date: 22/1/2008 Collection year: 2008
Full-Text HTML Views: 1199 Abstract HTML Views: 1061 PDF Downloads: 183 Total Views/Downloads: 2443
Full-Text HTML Views: 638 Abstract HTML Views: 671 PDF Downloads: 139 Total Views/Downloads: 1448 Geographical View
2008 Bentham Science Publishers Ltd.
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/) which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
* Address correspondence to this author at the Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; Tel: 507-266-5065; Fax: 507-284-3757; E-mail: email@example.com§These authors contributed equally.